SAN CARLOS, Calif., Aug. 1 /PRNewswire-FirstCall/ -- NeurogesX, Inc. , a biopharmaceutical company focused on developing novel pain management therapies, today announced it will report results for its second quarter of 2007 on Wednesday, August 8, 2007, after the market closes.
A conference call to review the results will begin at 4:30 p.m. EDT (1:30 p.m. PDT) on August 8, 2007 and will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer.
The conference call dial-in numbers are 1-877-407-0789 (USA) or 1-201-689-8562 (International). In addition, a dial-up replay of the conference call will be available beginning August 8, 2007 at 7:30 p.m. EDT (4:30 p.m. PDT) and ending on August 18, 2007. The replay telephone number is USA 1-877-660-6853, International 1-201-612-7415, Account Number: 3055, Conference ID Number: 249885.
A live web cast of the call will also be available from the Investor Relations section on the corporate web site at http://www.neurogesx.com. A web cast replay can be accessed on the corporate web site beginning August 8, 2007, at approximately 6:00 p.m. The replay will remain available until September 8, 2007.
About NeurogesX, Inc.
NeurogesX is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and diabetic neuropathy. NeurogesX’s late stage product portfolio is led by product candidate NGX-4010, a topical patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Two Phase III clinical trials with NGX-4010 have been completed and have met their primary endpoints, one in PHN and one in HIV-DSP.
NeurogesX, Inc. The Ruth Group Stephen Ghiglieri Investors / Media (650) 508-2116 Stephanie Carrington / Jason Rando (646) 536-7017 / 7025 scarrington@theruthgroup.comjrando@theruthgroup.com
NeurogesX, Inc.
CONTACT: Stephen Ghiglieri of NeurogesX, Inc., +1-650-508-2116; orInvestors, Stephanie Carrington, +1-646-536-7017,scarrington@theruthgroup.com, or Jason Rando, +1-646-536-7025,jrando@theruthgroup.com, both of The Ruth Group, for NeurogesX, Inc.
Web site: http://www.neurogesx.com/
